These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2809275)

  • 1. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
    Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
    Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
    Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
    N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG; Smith JW; Urba WJ; Venzon DJ; Longo DL; Barney R; Evans LM; Itri LM; Ewel CH
    Blood; 1991 Feb; 77(4):792-8. PubMed ID: 1704264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
    von Wussow P; Jakschies D; Freund M; Deicher H
    J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
    Antonelli G; Currenti M; Turriziani O; Dianzani F
    J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b.
    Glaspy JA; Souza L; Scates S; Narachi M; Blatt L; Ambersley J; Golde DW
    J Immunother (1991); 1992 Apr; 11(3):198-208. PubMed ID: 1381218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia.
    Slavikova M; Schmeisser H; Kontsekova E; Mateicka F; Borecky L; Kontsek P
    J Interferon Cytokine Res; 2003 Mar; 23(3):143-7. PubMed ID: 12716486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease.
    Ikeda Y; Miyake K; Toda G; Yamada H; Yamanaka M; Oka H
    J Gastroenterol Hepatol; 1989; 4(5):411-8. PubMed ID: 2491207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of response to interferon alpha-2b and the significance of antinuclear antibodies in hairy cell leukemia].
    Ríos R; Gascón F; Solé F; Garcia R; Vincente A; Ceballos P
    Med Clin (Barc); 1996 Apr; 106(15):583-5. PubMed ID: 8656758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
    Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
    J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
    Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
    Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-interferon antibody in chronic hepatitis C].
    Arai K; Shindo M; Okuno T
    Nihon Rinsho; 1994 Jul; 52(7):1929-34. PubMed ID: 7521441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-alpha-C.
    Aderka D; Levo Y; Rahmani R; Mory Y; Vaks B; Horowitz O; Doerner T; Shoham J; Wallach D; Revel M
    Isr J Med Sci; 1985 Dec; 21(12):977-81. PubMed ID: 4093298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstitution of endogenous interferon a by recombinant interferon in hairy cell leukemia.
    Shehata M; Schwarzmeier JD; Nguyen ST; Hilgarth M; Berger R; Hubmann R; Kickmaier S; Decker T
    Cancer Res; 2000 Oct; 60(19):5420-6. PubMed ID: 11034083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.
    Vedantham S; Gamliel H; Golomb HM
    Cancer Res; 1992 Mar; 52(5):1056-66. PubMed ID: 1737364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.